Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development
Recent data indicate increasing disease burden and importance of Plasmodium vivax (Pv) malaria. A robust assay will be essential for blood-stage Pv vaccine development. Results of the in vitro growth inhibition assay (GIA) with transgenic P. knowlesi (Pk) parasites expressing the Pv Duffy-binding pr...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2024
|
| _version_ | 1824459263649513472 |
|---|---|
| author | Mertens, JE Rigby, CA Bardelli, M Quinkert, D Hou, MM Diouf, A Silk, SE Chitnis, CE Minassian, AM Moon, RW Long, CA Draper, SJ Miura, K |
| author_facet | Mertens, JE Rigby, CA Bardelli, M Quinkert, D Hou, MM Diouf, A Silk, SE Chitnis, CE Minassian, AM Moon, RW Long, CA Draper, SJ Miura, K |
| author_sort | Mertens, JE |
| collection | OXFORD |
| description | Recent data indicate increasing disease burden and importance of Plasmodium vivax (Pv) malaria. A robust assay will be essential for blood-stage Pv vaccine development. Results of the in vitro growth inhibition assay (GIA) with transgenic P. knowlesi (Pk) parasites expressing the Pv Duffy-binding protein region II (PvDBPII) correlate with in vivo protection in the first PvDBPII controlled human malaria infection (CHMI) trials, making the PkGIA an ideal selection tool once the precision of the assay is defined. To determine the precision in percentage of inhibition in GIA (%GIA) and in GIA<sub>50</sub> (antibody concentration that gave 50 %GIA), ten GIAs with transgenic Pk parasites were conducted with four different anti-PvDBPII human monoclonal antibodies (mAbs) at concentrations of 0.016 to 2 mg/mL, and three GIAs with eighty anti-PvDBPII human polyclonal antibodies (pAbs) at 10 mg/mL. A significant assay-to-assay variation was observed, and the analysis revealed a standard deviation (SD) of 13.1 in the mAb and 5.94 in the pAb dataset for %GIA, with a LogGIA<sub>50</sub> SD of 0.299 (for mAbs). Moreover, the ninety-five percent confidence interval (95 %CI) for %GIA or GIA<sub>50</sub> in repeat assays was calculated in this investigation. The error range determined in this study will help researchers to compare PkGIA results from different assays and studies appropriately, thus supporting the development of future blood-stage malaria vaccine candidates, specifically second-generation PvDBPII-based formulations. |
| first_indexed | 2025-02-19T04:39:01Z |
| format | Journal article |
| id | oxford-uuid:18cd5054-427e-4395-a89e-dda076cc6ded |
| institution | University of Oxford |
| language | English |
| last_indexed | 2025-02-19T04:39:01Z |
| publishDate | 2024 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:18cd5054-427e-4395-a89e-dda076cc6ded2025-02-13T14:35:02ZEvaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine developmentJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:18cd5054-427e-4395-a89e-dda076cc6dedEnglishSymplectic ElementsElsevier2024Mertens, JERigby, CABardelli, MQuinkert, DHou, MMDiouf, ASilk, SEChitnis, CEMinassian, AMMoon, RWLong, CADraper, SJMiura, KRecent data indicate increasing disease burden and importance of Plasmodium vivax (Pv) malaria. A robust assay will be essential for blood-stage Pv vaccine development. Results of the in vitro growth inhibition assay (GIA) with transgenic P. knowlesi (Pk) parasites expressing the Pv Duffy-binding protein region II (PvDBPII) correlate with in vivo protection in the first PvDBPII controlled human malaria infection (CHMI) trials, making the PkGIA an ideal selection tool once the precision of the assay is defined. To determine the precision in percentage of inhibition in GIA (%GIA) and in GIA<sub>50</sub> (antibody concentration that gave 50 %GIA), ten GIAs with transgenic Pk parasites were conducted with four different anti-PvDBPII human monoclonal antibodies (mAbs) at concentrations of 0.016 to 2 mg/mL, and three GIAs with eighty anti-PvDBPII human polyclonal antibodies (pAbs) at 10 mg/mL. A significant assay-to-assay variation was observed, and the analysis revealed a standard deviation (SD) of 13.1 in the mAb and 5.94 in the pAb dataset for %GIA, with a LogGIA<sub>50</sub> SD of 0.299 (for mAbs). Moreover, the ninety-five percent confidence interval (95 %CI) for %GIA or GIA<sub>50</sub> in repeat assays was calculated in this investigation. The error range determined in this study will help researchers to compare PkGIA results from different assays and studies appropriately, thus supporting the development of future blood-stage malaria vaccine candidates, specifically second-generation PvDBPII-based formulations. |
| spellingShingle | Mertens, JE Rigby, CA Bardelli, M Quinkert, D Hou, MM Diouf, A Silk, SE Chitnis, CE Minassian, AM Moon, RW Long, CA Draper, SJ Miura, K Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development |
| title | Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development |
| title_full | Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development |
| title_fullStr | Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development |
| title_full_unstemmed | Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development |
| title_short | Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development |
| title_sort | evaluation of the precision of the plasmodium knowlesi growth inhibition assay for plasmodium vivax duffy binding protein based malaria vaccine development |
| work_keys_str_mv | AT mertensje evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT rigbyca evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT bardellim evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT quinkertd evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT houmm evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT dioufa evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT silkse evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT chitnisce evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT minassianam evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT moonrw evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT longca evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT drapersj evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment AT miurak evaluationoftheprecisionoftheplasmodiumknowlesigrowthinhibitionassayforplasmodiumvivaxduffybindingproteinbasedmalariavaccinedevelopment |